Stockreport

Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million

Elutia, Inc. - Class A  (ELUT) 
PDF - Transaction affirms the strength of Elutia’s proprietary drug-eluting biologics platform and fully funds advancement of NXT-41 in breast reconstruction - - Company to [Read more]